Clear All
12393 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
48433-0050-03 48433-0050 Imatinib Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 10, 2026 In Use
50090-7931-04 50090-7931 PREDNISONE PREDNISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Mar 10, 2026 In Use
00904-7584-10 00904-7584 Leucovorin Calcium Leucovorin Calcium 25.0 mg/1 Ancillary Therapy Chemoprotective Antidote Oral Mar 27, 2026 In Use
31722-0772-21 31722-0772 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
14789-0125-05 14789-0125 Cyclophosphamide Cyclophosphamide 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 30, 2026 In Use
68001-0246-04 68001-0246 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 13, 2018 In Use
50090-7933-00 50090-7933 PREDNISONE PREDNISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Mar 10, 2026 In Use
50090-7933-06 50090-7933 PREDNISONE PREDNISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Mar 24, 2026 In Use
50090-7935-00 50090-7935 PREDNISONE PREDNISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Mar 10, 2026 In Use
50268-0032-12 50268-0032 Abiraterone Acetate Abiraterone Acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 4, 2026 In Use
50881-0011-08 50881-0011 Ruxolitinib JAKAFI XR 11.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
50881-0022-08 50881-0022 Ruxolitinib JAKAFI XR 22.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
50881-0033-08 50881-0033 ruxolitinib JAKAFI XR 33.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
50881-0044-08 50881-0044 Ruxolitinib JAKAFI XR 44.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
50881-0055-08 50881-0055 Ruxolitinib JAKAFI XR 55.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
51662-1514-02 51662-1514 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Mar 31, 2020 In Use
55154-2581-00 55154-2581 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Mar 30, 2026 In Use
16729-0695-06 16729-0695 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 2, 2026 In Use
43066-0001-01 43066-0001 docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb 19, 2018 In Use
68071-3721-01 68071-3721 PREDNISONE PREDNISONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec 19, 2024 In Use
16729-0696-06 16729-0696 Lenalidomide Lenalidomide 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 26, 2026 In Use
61786-0027-57 61786-0027 Methylprednisolone Acetate Depo-Medrol 80.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intralesional, Intramuscular, Intrasynovial, Soft Tissue Sep 11, 2014 Sep 27, 2018 In Use
55513-0160-01 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Dec 18, 2014 In Use
55513-0160-21 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Apr 30, 2026 In Use
60505-4500-02 60505-4500 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 11, 2026 In Use

Found 12393 results — Export these results